NASDAQ$TGTX
TG Therapeutics Inc. · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
TG Therapeutics reported a net loss for Q2 2022, but cost-saving measures resulted in a lower-than-expected burn rate. The company is focused on obtaining FDA approval for ublituximab for relapsing forms of multiple sclerosis (RMS).
TG Therapeutics reported its Q2 2022 financial results, showing a net loss of $40.5 million. The company's primary focus is on gaining FDA approval for ublituximab for RMS, with a PDUFA goal date of December 28, 2022. Cost-saving measures have been implemented, leading to a reduced cash burn.
- FDA accepted the BLA for ublituximab for RMS with a PDUFA goal date of December 28, 2022.
- Presented new exploratory analyses from the ULTIMATE I and II Phase 3 trials at CMSC and EAN, demonstrating a statistically significant reduction in ARR with ublituximab compared to teriflunomide.
- Net loss for the quarter was $40.5 million, a decrease compared to $78.5 million in Q2 2021, due to cost-saving measures and the withdrawal of UKONIQ.
- Cash, cash equivalents, and investment securities totaled $231.8 million as of June 30, 2022, expected to fund operations into the second half of 2023.
Headline financials
Revenue & EPS history
TG Therapeutics · Revenue · Quarterly
$594K
Forward guidance
TG Therapeutics anticipates an increase in selling, general, and administrative expenses as it prepares for the potential launch of ublituximab in RMS. The company believes its current cash position will be sufficient to fund operations into the second half of 2023.
Tailwinds
- Potential FDA approval of ublituximab by December 28, 2022.
- Ublituximab has the potential to be a meaningful treatment option for patients with relapsing forms of multiple sclerosis.
- Cost-saving measures have been implemented, resulting in a lower than expected 2Q burn.
- Company believes it is in a good financial position as it approaches the potential launch of ublituximab.
- Cash position expected to fund operations into the second half of 2023.
Headwinds
- Forward-looking statements are subject to risks and uncertainties.
- Potential for variation from the Company’s projections and estimates about the potential market for ublituximab.
- Risk that regulatory authorities disagree with the conclusions reached or data disclosed.
- Reliance on third parties to perform manufacturing, distribution and supply services.
- Risk that the ongoing COVID-19 pandemic and associated government control measures have an adverse impact on clinical trials and other research and development plans.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+2.7%
Avg return
Earnings day
+5.5%
Avg return
5 days after
+4.1%
Avg return
30 days after
49%
27 / 55 earnings
Positive
+81.0%
Q3 2022
Best reaction
-49.0%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +16.3% | +19.4% | +11.1% | |
| Q4 2025 | +4.3% | -2.6% | +7.0% | |
| Q3 2025 | -1.0% | -7.3% | -9.1% | |
| Q1 2025 | -13.4% | -22.6% | -14.7% | |
| Q4 2024 | +14.4% | +27.8% | +32.3% | |
| Q3 2024 | -3.9% | +7.1% | +25.9% | |
| Q2 2024 | +16.2% | +15.7% | +24.7% | |
| Q1 2024 | +20.2% | +20.9% | +19.3% | |
| Q4 2023 | +23.8% | +28.5% | +9.3% | |
| Q3 2023 | +34.7% | +32.6% | +78.9% | |
| Q2 2023 | -49.0% | -48.2% | -49.4% | |
| Q1 2023 | +25.5% | +38.1% | +7.2% | |
| Q4 2022 | -3.8% | +7.8% | -8.2% | |
| Q3 2022 | +81.0% | +70.7% | +45.7% | |
| Q2 2022 | +19.4% | +33.4% | +9.1% | |
| Q1 2022 | -10.9% | +1.4% | -24.5% | |
| Q4 2021 | +4.7% | -11.1% | -3.6% | |
| Q3 2021 | +7.9% | +5.3% | -52.5% | |
| Q2 2021 | -27.2% | -32.8% | -15.8% | |
| Q1 2021 | -6.7% | -14.8% | -7.2% | |
| Q4 2020 | -5.0% | -3.8% | +8.8% | |
| Q3 2020 | -0.2% | +4.4% | +5.0% | |
| Q2 2020 | -12.0% | +2.6% | +22.3% | |
| Q1 2020 | +5.9% | +2.6% | -6.0% | |
| Q4 2019 | -4.1% | -13.6% | -32.6% | |
| Q3 2019 | +1.4% | +2.7% | +20.6% | |
| Q2 2019 | +3.3% | +0.1% | -8.4% | |
| Q1 2019 | -15.5% | -13.4% | -8.0% | |
| Q4 2018 | +0.4% | -8.1% | +18.2% | |
| Q3 2018 | +2.5% | -1.1% | -4.4% | |
| Q2 2018 | -3.4% | -0.4% | +0.0% | |
| Q1 2018 | -3.7% | -2.6% | +3.7% | |
| Q4 2017 | +8.5% | +10.2% | -15.1% | |
| Q3 2017 | +9.9% | +9.3% | +12.6% | |
| Q2 2017 | +1.0% | +16.0% | +22.0% | |
| Q1 2017 | +2.5% | +11.3% | +36.5% | |
| Q4 2016 | +3.4% | +22.5% | -10.6% | |
| Q3 2016 | +1.0% | +6.7% | -1.9% | |
| Q2 2016 | -7.6% | -0.2% | +13.3% | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | -6.8% | — | — | |
| Q3 2015 | +8.4% | — | — | |
| Q2 2015 | -2.2% | — | — | |
| Q1 2015 | -6.0% | — | — | |
| Q3 2014 | +14.6% | — | — | |
| Q1 2012 | -3.7% | — | — | |
| Q2 2012 | -14.3% | — | — | |
| Q4 2011 | -23.0% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +36.4% | — | — | |
| Q4 2010 | +7.7% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro